Navigation Links
Data Presented at Society of Nuclear Medicine 2009 Annual Meeting Supports Potential of Peregrine's Cotara(R) for the Treatment of Brain Cancer
Date:6/16/2009

to share this promising data from our current U.S.

Cotara clinical trial with experts at this prestigious conference, and we look forward to reporting further data from this study and from our Phase II trial in patients with recurrent GBM."

More than 65 patients with recurrent GBM have received Cotara in the current and previous clinical studies. Localization and accumulation of the drug to the tumor have been excellent and longer-term survivors (greater than one year from the time of Cotara treatment) have been observed in all of the trials, with some GBM patients from early clinical studies now alive more than 8.5 years after treatment with Cotara. Expected survival for patients with GBM is approximately six months from the time of disease recurrence.

The Cotara data will be presented today at the 2009 Society for Nuclear Medicine (SNM) Annual Meeting in Toronto, Canada, in a session scheduled from 12:30 PM to 2:00 PM EDT in Room 701B.

Abstract No: 150240; Publication No: 445: S. Shen(1), R. Lustig(2), K. Judy(2), W. Shapiro(3), K. Spicer(4), S. Patel(4), J. Fiveash(1), J. Lai(5), J. Shan(5), "Dosimetry of phase I interstitial 131I-chTNT-1/B MAb (Cotara) for the treatment of recurrent glioma."

(1)U Alabama, Birmingham, AL; (2)U Penn, Philadelphia, PA; (3)BNI St. Joseph's MedCtr, Phoenix, AR; (4)Med U S Carolina, Charleston, SC; (5)Peregrine Pharma Inc, Tustin, CA

About Cotara(R)

Cotara is an experimental treatment for brain cancer that links a radioactive isotope to a targeted monoclonal antibody designed to bind to the DNA histone complex that is exposed by dead and dying cells found at the center of solid tumors. Cotara's targeting mechanism enables it to bind to the dying tumor cells, delivering its radioactive payload to the adjacent living tumor cells and essentially destroying the tumor from the inside out, with minimal radiation exposure to
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Three Studies by Independent Scientists Highlighting Pressure Cycling Technology (PCT) to be Presented this Week at the British Mass Spectrometry Societys 29th Annual Meeting
2. Survival Data Presented From Phase II Study of Investigational Drug ZD4054 in Hormone-Resistant Prostate Cancer Patients
3. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
4. Results of Colon Cancer Study Utilizing Pressure Cycling Technology (PCT) Presented at the American College of Gastroenterology Annual Scientific Meeting
5. Kuvan, Naglazyme and Aldurazyme Data to Be Presented at the 57th Annual Meeting of the American Society of Human Genetics
6. Micromet Data Presented at the International AACR-NCI-EORTC Conference Support the Development of Adecatumumab (MT201) in Earlier Stage Cancer Disease Settings
7. Three PDX (Pralatrexate) Studies Presented at the 2007 AACR-NCI-EORTC Conference
8. Salugens Award-Winning Research on Using DNA Information to Customize Nutritional Supplementation for Weight Loss Presented at the Second Annual Bruce Ames International Symposium on Nutritional Genomics at the University of California, Davis
9. Reverse Cholesterol Transport by RVX-208 a Small Molecule for ApoA-I Production Increase Presented at American Heart Association Scientific Meeting
10. Genasense(R) Triple Combination Therapy in Advanced Melanoma Presented at Chemotherapy Foundation Symposium
11. Promising Data ATIR Studies Presented by NIH Investigators
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Dr. Greg Leyer of UAS Labs recently was invited ... seminar on probiotics in San Diego, CA. , The ... for health care professionals. This year’s pre-conference seminar was held ... health. Dr. Leyer spoke about the emerging topics and science ...
(Date:1/22/2015)... SAN DIEGO , Jan. 22, 2015   ... company, and Sequenom, Inc. (NASDAQ: SQNM ... a development agreement for next generation noninvasive prenatal ... Cypher,s genome interpretation technology, called Mantis™, to advance ...
(Date:12/24/2014)... Md. , Dec. 24, 2014  United Therapeutics Corporation ... Inc. (NYSE: MDT ) has submitted a ... Administration (FDA) for the use of Medtronic,s SynchroMed ® ... developed catheter) for use with United Therapeutics, Remodulin ® ...
(Date:12/24/2014)... St. Louis, Missouri (PRWEB) December 23, 2014 ... Swiss biotechnology company, Syngenta, are in the process of being ... consolidated case is In Re: Syngenta AG MIR 162 Corn ... the District of Kansas. , Management of the Syngenta GMO ...
Breaking Biology Technology:Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2
... While I have touted using fiber-optics for years because ... be the more cost-effective way to go for network ... writes adjunct Northwestern professor James Carlini. , ,Copper ... by some analysts on Wall Street. If they ...
... If chief information officers are to enjoy successful tenures within ... to blow their own horns. , ,That was one of ... annual Wisconsin IT Symposium hosted by the Milwaukee IT Leadership ... held at the Milwaukee West Marriott, attracted technology executives from ...
... product billed as the world's first and only compact ... approval and now is commercially available in the United ... billion unit of General Electric Co., has received U.S. ... a compact ultrasound system with 4D imaging capabilities. The ...
Cached Biology Technology:With copper pricing skyrocketing, fiber-optics is the way to go 2With copper pricing skyrocketing, fiber-optics is the way to go 3With copper pricing skyrocketing, fiber-optics is the way to go 4Advanced CIO: Technology execs must trumpet their success 2Advanced CIO: Technology execs must trumpet their success 3Advanced CIO: Technology execs must trumpet their success 4GE introduces compact ultrasound system for women 2
(Date:12/24/2014)... , Dec. 23, 2014  Since its launch in December 2014, ... to eliminate the pain of trying to remember their usernames ... biometrics fused to their smartphones. To assist people who have ... the company that created 1U and focuses on redefining identity, ...
(Date:12/19/2014)... , Dec. 18, 2014 Research and Markets ... the "iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... Apple introduced the fingerprint reading feature with the iPhone ...
(Date:12/17/2014)... Research and Markets ( http://www.researchandmarkets.com/research/s6qzt5/samsung_galaxy_s5 ) has ... - Home Button Synaptics Fingerprint Sensor Technology Analysis" ... http://photos.prnewswire.com/prnh/20130307/600769 Based on a totally different ... the first time a fingerprint sensor in its product. ...
Breaking Biology News(10 mins):1U Offers Best Solution to the Username / Password Dilemma: For FREE! 21U Offers Best Solution to the Username / Password Dilemma: For FREE! 3iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology Report 2Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2
... Epitomics, Inc. announced today that it has signed a ... HealthCare). Epitomics will use its proprietary rabbit monoclonal antibody ... identification and validation. "Epitomics has had ... is a major expansion of our collaboration and confirms ...
... German . Medicines from plants ... that has nothing in common with what the researchers ... Ecology IME in Aachen, Germany, are doing. They use ... many other medications, cannot be chemically produced. Biologically ...
... persist in the often violently competitive realm of bacteria, ... University Bloomington biologists have learned that in one bacterium, ... cheaters and arrest their bids for dominance. ... suppress social cheaters," said Gregory Velicer, who with Ph.D. ...
Cached Biology News:Medicines from plants 2'Policing' stops cheaters from dominating groups of cooperative bacteria 2'Policing' stops cheaters from dominating groups of cooperative bacteria 3'Policing' stops cheaters from dominating groups of cooperative bacteria 4
... Synergistic enzyme mix (Thermoprime Plus DNA ... At least four times higher fidelity than ... of standard Taq DNA polymerase, Amplifies DNA ... PCR, long PCR, PCR for cloning and ...
... Assay Kit (E-22013) provides,researchers with a ... lysozyme,activity in solution. This fluorescence-based assay ... U/mL (Figure 1). The assay,measures lysozyme ... are labeled to such a degree ...
... An immuncapture enzyme-activity assay based on ... captured on monoclonal antibody coated microtiter plate. ... standards, samples or controls, 2nd ... The assay is intended for the determination ...
... HT is designed for extended ... HT is ideal for applications ... primer extension assays. iEMS Incubator/Shaker ... one-cabinet model, allowing the capacity ...
Biology Products: